期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

治疗2型糖尿病的新药Canagliflozin 被引量：1

下载PDF
导出
摘要 2型糖尿病（T2DM）是一种常见的慢性疾病,是以糖代谢自身稳定控制功能受损而致高血糖为特征的综合征,约占所有糖尿病病例的90%[1].美国约有2 500万的成人糖尿病患者,其死亡风险是无糖尿病者的2倍.我国的成人糖尿病患病率约为9.7%,患者总数超过9 000万,约占全球糖尿病患者总数的1/3[2].
作者 夏玲红 孙黎 王淑萍 杨娟
机构地区 上海交通大学医学院附属仁济医院药剂科
出处 《中国药师》 CAS 2014年第3期487-489,共3页 China Pharmacist
关键词 Canagliflozin 2型糖尿病 降糖药
分类号 R977.15 [医药卫生—药品]
  • 相关文献

参考文献15

  • 1安富荣,崔岚,王勤.治疗2型糖尿病新药二肽基肽酶-4抑制药阿格列汀[J].中国药师,2012,15(1):116-118. 被引量：15
  • 2中华医学会糖尿病学分会.中国2型糖尿病防治指南(2010年版)[J].中国医学前沿杂志(电子版),2011,6(3):54109.
  • 3Bakris GL, Fonseca VA, Sharma K, et al. Renal-sodium glucose transport: role in diabetes mellitus and potential clinical implications [J]. Kidney lnt,2009, 75(2) :1272-1277.
  • 4Neumiller JJ, White JR, Campbell RK. Sodium-glucose co-transport inhibitors [ J ]. Drugs, 2010, 70 (4) :377-385.
  • 5Sha S, Devineni D, Gosh A, et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose ex- cretion in healthy subjects [ J]. Diabetes Obes Metab, 2011, 13 (7) : 669-672.
  • 6Devineni D, Curtin CR, Polidori D, et al. Pharmacokinetics and pharmacodynamies of eanagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjeets with type 2 diabetes mellitus [ J]. J Clin Phar- macol, 2013, 53(6) :601-610.
  • 7Lamos EM, Younk LM, Davis SN. Canagliflozin , an inhibitor of so- dium-glucose cotransporter 2, for the treatment of type 2 diabetes mel- litus[J]. Expert Opin Drug Metab Toxicol, 2013, 9(6) :763-775.
  • 8Devineni D, Morrow L, Hompesch M, et al. Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not op- timally controlled on insulin [ J ]. Diabetes Obes Metab, 2012, 14 (6) :539-545.
  • 9Stenl~f K, Cefalu WT, Kim KA, et al. Efficacy and safety of canagli- flozin in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise [ J ]. Diabetes Obes Metab, 2013, 15 (4) :372- 382.
  • 10Bode B, Stenlfif K, Sullivan D, et al. Efficacy and safety of canagli- flozin treatment in older subjects with type 2 diabetes mellitus : a ran- domized trial [J]. Hosp Pract, 2013, 41 (2) :72-84.

二级参考文献15

  • 1Scott LJ.Alogliptin:a review of its use in the management of type 2 diabetes mellitus[J].Drugs,2010,70 (15):2051-2072.
  • 2Ghatak SB,Patel DS,Shanker N,et al.Alogliptin:a novel molecule for improving glycemic control in type Ⅱ diabetes mellitus[J].Curr Diabetes Rev,2010,6 (6):410-421.
  • 3Karim A,Covington P,Christopher R,et al.Pharmacokinetics of alogliptin when administered with food,metformin,or cimetidine:a twophase,crossover study in healthy subjects[J].Int J Clin Pharmacol Ther,2010,48 (1):46-58.
  • 4Christopher R,Covington P,Davenport M,et al.Pharmacokinetics,pharmacodynamics,and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects[J].Clin Ther,2008,30 (3):513-527.
  • 5Covington P,Christopher R,Davenport M,et al.Pharmacokinetic,pharmacodynamic,and tolerability profiles of the dipeptidyl peptidase4 inhibitor alogliptin:a randomized,double-blind,placebo-controlled,multiple-dose study in adult patients with type 2 diabetes[J].Clin Ther,2008,30 (3):499-512.
  • 6Fleck P,Christopher R,Covington P,et al.Efficacy and safety of alogliptin monotherapy over 12 weeks in patients with type 2 diabetes[J].Diabetes,2008,57 (Suppl.1):143.
  • 7DeFronzo RA,Fleck PR,Wilson CA,et al.Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control:a randomized,double-blind,placebo-controlled study[J].Diabetes Care,2008,31 (12):2315-2317.
  • 8Nauck MA,Ellis GC,Fleck PR,et al.Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metfonnin monotherapy:a multicentre,randomised,double-blind,placebo-controlled study[J].Int J Clin Pract,2009,63 (1):46-55.
  • 9Rosenstock J,Rendell MS,Gross JL,et al.Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA1C without causing weight gain or increased hypoglycaemia[J].Diabetes Obes Metab,2009,11 (12):1145-1152.
  • 10Pratley RE,Reusch JE,Fleck PR,et al.Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes:a randomized,double-blind,placebo-controlled study[J].Curr Med Res Opin,2009,25 (10):2361-2371.

共引文献126

同被引文献12

  • 1Balakumar P, Sundram K, Dhanaraj SA. et al. Dapagliflozin: Glucu- retic action and beyond[J]. Pharmacol Res, 2014, (82C) :34-39.
  • 2Tahrani AA, Barnett AH, Bailey CJ, et al. SGLT inhibitors in man- agement of diabetes[J]. Lancet Diabetes Endocrinol, 2013,1(2) :140- 151.
  • 3Chen J, Williams S, Ho S, et al. Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members [ J ]. Diabetes, 2010,1 (2) :57-92.
  • 4Wright EM. Renal Na + -glucose cotransporters [ J ]. Am J Physiol Re- nal Physiol, 2001, 280(1) : F10-F18.
  • 5US Food and Drug Administration. FDA labelling information FARXI- GA. FDA website[EB/OL], http://www, accessdata, fda. gov/drug- satf da_docs/ label/ 2014 / 20229 3 sOOO lbl. pdf ,2014-01-08 /2014-01 -18.
  • 6Merovci A, Solis-Herrera C, Daniele G, et al. Dapagliflnzin improves muscle insulin sensitivity but enhances endogenous glucose production [J]. J Clin Invest, 2014, 124(2) :509-514.
  • 7Yang L, Li H, Li H, et al. Pharmacokinetic and pharmacodynamic properties of single- and multiple-dose of dapagliflozin, a selective in- hibitor of SGLT2, in healthy Chinese subjects[J]. Clin Ther, 2013, 35(8) :1211-1222.
  • 8Kasichayanula S, Chang M, Liu X, et al. Lack of pharmacokinetic in- teractions between dapagliflozin and simvastatin, valsartan, warfarin, or digoxin[J]. Adv Ther, 2012, 29(2) :163-177.
  • 9Bailey C J, Gross JL, Hennicken D, et al. Dapagliflozin add-on to met- formin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial [ J ]. BMC Meal.2013, 20( 11 ) :43.
  • 10Nauck M, del Prato S, Meier JJ, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin[ J]. Dtsch Med Wochenschr, 2013,138 (Suppl 1 ) :S6-15.

引证文献1

二级引证文献15

中国药师
2014年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部